CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

TP53 deletion / del(17p) (chronic lymphocytic leukemia)

Gene: TP53 · Type: deletion

Indications: Chronic lymphocytic leukemia

Linked CIViC Profile: TP53 MUTATION

Evidence Level Distribution

Level A: 1Level B: 22Level C: 2Level D: 2
LevelTypeDirectionSignificanceDiseaseDrugsRating
BPrognosticSupportsPoor OutcomeChronic Lymphocytic Leukemia5
BPrognosticSupportsPoor OutcomeChronic Lymphocytic Leukemia5
APrognosticSupportsPoor OutcomeChronic Lymphocytic Leukemia5
BPrognosticSupportsLung Non-small Cell Carcinoma5
BPrognosticSupportsPoor OutcomeMedulloblastoma SHH Activated5
BPrognosticSupportsPoor OutcomeEsophagus Squamous Cell Carcinoma4
BPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphoma4
BPrognosticSupportsPoor OutcomeMyelodysplastic Syndrome4
BPrognosticSupportsPoor OutcomeMyeloid Neoplasm4
BPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell Carcinoma4
BPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell Carcinoma4
BPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphoma4
DPredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicin4
BPrognosticSupportsPoor OutcomeAcute Myeloid Leukemia4
BPrognosticSupportsPoor OutcomeChronic Lymphocytic Leukemia4
BPredictiveSupportsSensitivity/ResponseMyelodysplastic SyndromeAzacitidine,Eprenetapopt4
BPrognosticSupportsPoor OutcomeBreast Cancer3
BPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell Carcinoma3
BPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaChemotherapy3
DPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,Docetaxel3